Thank you for participating in the 81st Scientific Sessions!
More than 11,500 participants from almost 120 countries took part in the five days of groundbreaking science presented at the 81st Scientific Sessions. Planning is underway for the 82nd Scientific Sessions, scheduled for June 2022 in New Orleans.
A1C is routinely used to monitor glycemic control for patients with diabetes. At the Scientific Sessions, Jay H. Shubrook, DO, FACOFP, FAAFP, BC-ADM, and David B. Sacks, MB ChB, FACP, FRCPath, debated whether point-of-care A1C should be part of the diagnostic toolkit for diabetes. Read more
Marcela Brissova, PhD, Struan F.A. Grant, PhD, Maggie Ng, PhD, and Melina Claussnitzer, PhD, discussed how molecular and genetic studies are providing new insight into the influence of genetics in the development and progression of diabetes. Read more
“The KPMP is all about using the kidney biopsy, which is an old tool, to understand kidney disease in a new way by almost turbocharging the information that we get,” said Jonathan Himmelfarb, MD. Read more
New research uses single-cell technologies to explore the roles of adipocytes, macrophages, beta cells, and fibroblast growth factor-1 in metabolic tissue function. Qiong (Annabel) Wang, PhD, Christopher K. Glass, MD, PhD, Heiko Lickert, PhD, and Michael W. Schwartz, MD, reviewed this work at the Scientific Sessions. Read more
Brian A. Ference, MD, MPhil, MSc, FACC, FESC, Lisa R. Tannock, MD, Jean-Claude Tardif, CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS, and Stephen G. Young, MD, discussed new insights into the role of triglycerides in cardiovascular disease at the Scientific Sessions. Read more
A symposium sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases showcased current research by six young scientists—Emily K. Sims, MD, Emilyn U. Alejandro, PhD, Rafael Arrojo e Drigo, PhD, Camille E. Powe, MD, Rochelle N. Naylor, MD, and Joshua J. Joseph, MD, MPH, FAHA—aimed at developing a more stratified medical approach to diabetes from the bench to bedside. Read more
Patients have rallied behind the development of do-it-yourself automated insulin delivery systems to manage their diabetes. Natalie J. Bellini, MSN, FNP-BC, Dana Lewis, BA, Anna Norton, MS, and David M. Maahs, MD, PhD, discussed potential ramifications for patients, clinicians, researchers, and even manufacturers of commercial closed-loop devices. Read more
“Equity is our goal,” said Tiffany L. Gary-Webb, PhD, MHS. “But the reality is right now we’re not anywhere near that. The reality is that some people have much more than they need and there are other people who are digging themselves out of a hole.” Read more
Jonathan Z. Long, PhD, Yu-Hua Tseng, PhD, Kristin I. Stanford, PhD, and Anthony W. Ferrante, MD, PhD, discussed emerging understanding of how organ systems communicate to regulate and maintain energy homeostasis. Read more
Recent and emerging research sheds new light on the role of beta cells in the development and progression of type 1 diabetes. Carmella Evans-Molina, MD, PhD, explained the association between beta cell function and immune therapy efficacy. Read more
Four experts—Tammer Elmarsafi, DPM, MBBCh, Foluso Fakorede, MD, Garneisha Torrence, DPM, MHMS, and Michael D. VanPelt, DPM—discussed surgical considerations in diabetes foot management at the Scientific Sessions. Read more
Samuel Klein, MD, and Blandine Laferrère, MD, PhD, presented different viewpoints on whether the metabolic benefits of Roux-en-Y gastric bypass surgery are due to weight loss alone. Read more
Maria S. Remedi, PhD, Richard O’Brien, PhD, Aleksey Matveyenko, PhD, and Jennifer Bruin, PhD, explained several ways that diet and environmental factors can affect beta cell function, metabolic disease, and diabetes during the Scientific Sessions. Read more
A panel of investigators including Billy Tsai, PhD, Peter Thompson, MSc, PhD, Emily May Walker, PhD, and Ernesto Nakayasu, PhD, BS, discussed how emerging and ongoing research into the mechanisms of beta cell senescence is providing new insight into the roles of beta cell aging and stress in the development and progression of diabetes. Read more
Eleanor M. Scott, BM, BS, MD, FRCP, was one of five experts who addressed the utility of continuous glucose monitoring during pregnancy. A functional data analysis of two recent studies highlights the importance of tight glucose targets before the end of the first trimester for normal fetal growth, Dr. Scott said. Read more
Four researchers—Emily J. Gallagher, MD, PhD, MRCPI, M. Celeste Simon, PhD, Lydia Finley, PhD, and Marcus Goncalves, MD, MSE, PhD—looked at the connections between insulin and cancer during the Scientific Sessions. Read more
“It will be primary prevention that can be applied to a large number of the population that will really make an impact to the incident numbers of type 1 diabetes,” said Ezio Bonifacio, PhD. Read more
Wendy M. Kohrt, PhD, Karyn A. Esser, PhD, and K. Sreekumaran Nair, MD, principal investigators from the Molecular Transducers of Physical Activity Consortium, discussed how early data from animal studies is setting the stage for human studies. Read more
The pandemic exacerbated gender inequities among health care providers. In the U.S., 73% of health care providers who tested positive for COVID-19 were women. The ADA’s network for female clinicians, scientists, educators, and other health professionals discussed the impact of this and strategies to close leadership gaps. Read more
Experts in four rare forms of diabetes discussed strategies for diagnosing and treating patients with these atypical conditions during the Scientific Sessions. The session featured Janet B. McGill, MD, Marina Basina, MD, Armen Yerevanian, MD, and Mark S. Anderson, MD, PhD. Read more
A panel of physician-scientists including Ralph A. DeFronzo, MD, Chantal Mathieu, MD, PhD, Tina Vilsbøll, MD, DMSc, and David D’Alessio, MD, discussed the current evidence for combination therapies in the treatment of type 2 diabetes. Read more
Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC, Muthiah Vaduganathan, MD, MPH, Brendon Neuen, MBBS (Hons), MSc (Oxon), and David C. Wheeler, MD, FRCP, reviewed recent trial results demonstrating the safety and efficacy of SGLT2 inhibitors for both cardiovascular and renal treatment, and discussed how those trial results will help improve care for people with diabetes. Read more
Nigel A. Calcutt, PhD, Fabiana Picconi, MD, Karolina S. Khan, MD, PhD, and Kara R. Mizokami-Stout, MD, made up a panel of researchers who discussed some of the most challenging issues they face while investigating methods to prevent and treat diabetic neuropathies. Read more
Camillo Ricordi, MD, FNAI, Thierry Berney, MD, A.M. James Shapiro, MD, PhD, and Piotr Witkowski, MD, PhD, explained what has led to pancreatic islet transplantation effectively halting in the United States while the procedure has become standard of care in much of the rest of the world. Read more
“Stress is epidemic in the U.S. and other Western [countries], and most of our stressors are social,” said Carol A. Shively, PhD, in a session on the influence of social stress and social inequalities on metabolic health. She presented evidence based on animal models. Mika Kivimäki, PhD, FMedSci, presented evidence of the correlation between socioeconomic status and health. Read more
Investigators presented findings from the GRADE study comparing clinical outcomes of glimepiride, a sulfonylurea; sitagliptin, a DPP-4 inhibitor; insulin Lantus; and liraglutide, a GLP-1 receptor agonist. More than 70% of participants reached the primary metabolic endpoint. Read more
An analysis of the SCORED and SOLOIST trials favored sotagliflozin over placebo for total cardiovascular death, hospitalization for heart failure, and urgent heart failure visit. The combined SGLT1/SGLT2 inhibitor produces benefits in patients with reduced and preserved ejection fraction, said Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC. Read more
“The road ahead for the treatment of type 2 diabetes is fresh," said Alice Y.Y. Cheng, MD. "The future, in terms of what we will be able to offer our patients to help them meet their metabolic goals, appears to be very positive.” Read more
The efficacy and safety outcomes of efpeglenatide are similar to the outcomes seen in trials of other GLP-1 receptor agonists, according to researchers who presented AMPLITUDE-O data at the Scientific Sessions. Read more
DARE-19 was the first large, randomized clinical trial of an SGLT2 inhibitor to address the potential benefits of these agents in patients hospitalized with COVID-19. Results showed no significant effect on organ failure or survival. Mikhail N. Kosiborod, MD, was the principal investigator. Read more
ADA CEO sets sights on equity and outcomes post-COVID
ADA CEO Tracey D. Brown, MBA, BChE, discusses the work the ADA has continued to do during the COVID-19 pandemic and where the association will focus its efforts in the diabetes community going forward. She also delivered remarks to the 81st Scientific Sessions on Saturday morning, and that on-demand video can be viewed at ADA2021.org.
#ADA2023 Live Coverage
Q&A: Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials
Clockwise from top left, Deepak Bhatt, MD, MPH, Mikhail N. Kosiborod, MD, Subodh Verma, MD, PhD, FRCSC, Julie Lewis, MD, and Larry Leiter, MD, discuss questions from Scientific Sessions attendees following a Tuesday symposium on SCORED and SOLOIST trial results. View this session and the Q&A discussion on-demand.
#ADA2023 Social Scene
Loading...
#ADA2023 Live Coverage
Translating Diabetes and Kidney Disease Clinical Trial Findings into Clinical Practice
Jennifer B. Green introduces a symposium about how to translate clinical trial findings related diabetes and kidney disease into clinical practice. View this session.
#ADA2023 Live Coverage
Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials
The results of cardiovascular and kidney outcomes trials are the focus of a symposium featuring Subodh Verma, MD, PhD, FRCSC, (pictured) sharing insights from SOLOIST, and Mikhail N. Kosiborod, sharing insights from SCORED. The session includes a live video question and answer period starting at 12:03 p.m. ET. This discussion will be available for viewing with the on-demand session recording at ADA2021.org within 24 hours.
#ADA2023 Live Coverage
Debate—Precision Nutrition—Are We There Yet?
Kevin D. Hall, PhD, and Paul W. Franks, PhD, debate whether precision nutrition is ready for prime time. View this session.
#ADA2023 Live Coverage
Single-Cell Perspectives on Metabolic Tissue Function
Carey N. Lumeng, MD, PhD, moderates a Tuesday morning symposium discussing single-cell perspectives on metabolic tissue function. View this session.
#ADA2023 Live Coverage
Q&A: Next Chapter in Incretin-Based Therapies—Tirzepatide, a Novel Dual GIP/GLP-1 Receptor Agonist—Results from the First Phase 3 SURPASS Clinical Trials
Clockwise from top left, Alice Y.Y. Cheng, MD, FRCPC, Francesco Giorgino, MD, PhD, Daniel J. Drucker, MD, Michelle Welch, MD, FACE, Carol H. Wysham, MD, and Juan Pablo Frias, MD, discuss questions from Scientific Sessions attendees following a Tuesday morning symposium on SURPASS trial results. View this session and the Q&A discussion on-demand.
#ADA2023 Live Coverage
Q&A: Results of the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) Study
David M. Nathan, MD, Hertzel C. Gerstein, MD, MSc, FRCPC, John B. Buse, MD, PhD, Deborah Wexler, MD, MSc (top row); John M. Lachin, ScD, Steven E. Kahn, MB, ChB, Julio Rosenstock, MD, Heidi Krause-Steinrauf, MS (middle row); Mary Larkin, MS, RN, Margaret A. Tiktin, DNP, CNP, MBA, and David R. Matthews, (bottom row), DPhil, FRCP, discuss questions from Scientific Sessions attendees following a Monday afternoon symposium on GRADE trial results. View this session and the Q&A discussion on-demand.
A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin from 10:15 a.m. – 12:15 p.m. ET.
Learn about the benefits of ADA membership, including educational resources, an online forum for professionals at all stages of their careers, Professional Interest Groups, the Women's Interprofessional Network of ADA (WIN ADA), journals and books, a patient education library, and more. Become a member today.
#ADA2023 Live Coverage
Insulin as a Driver of Cancer
Lewis C. Cantley begins a symposium on insulin as a driver of cancer. Topics include the role of systemic metabolism in shaping tumor development, obesity-related cancers, metabolic pathways as determinants of cancer cell fate decisions, and diet as both a cause and an intervention for cancer. View the session.
Systemic health inequity contributes to worse outcomes and higher risk for diabetes and many other diseases. The ADA makes a call for ensuring health equity for all. Learn more at diabetes.org/HealthEquityNow.
Maryam Afkarian, MD, PhD, will explore some of the challenges to the practical application of tools to manage diabetes and kidney disease in a symposium beginning at 9:00 a.m. ET.
Tuesday Highlights at the 81st Scientific Sessions
Scientific Sessions Meeting Planning Committee Chair Dana Dabelea, MD, PhD, previews the highlights of the educational program on the final day of the virtual meeting.
#ADA2023 Live Coverage
Translating Diabetes and Heart Failure Clinical Trial Findings into Clinical Practice
Javed Butler, MD, MPH, MBA, serves as chair of a symposium discussing how to apply clinical trial findings to clinical practice as it relates to diabetes and heart failure—with reduced ejection fraction and with preserved ejection fraction. View the session.
New, detailed results of the first Phase 3 SURPASS clinical trials involving tirzepatide will be presented in a dedicated symposium at 8 a.m. “The glucose-lowering and weight reductions of this dual incretin receptor agonist are unprecedented,” said Julio Rosenstock, MD.
Paul W. Franks, PhD, and Kevin D. Hall, PhD, will present opposing viewpoints about whether the hype about precision nutrition outweighs the science during a debate at 8:00 a.m. ET on the final day of the Scientific Sessions.
Manoj Bhasin, PhD, MS, will unveil some of the latest developments in multi-dimensional and spatial single-cell omics in a session beginning at 8:00 a.m. ET.
Michelle M. Kittleson, MD, PhD, and Nasrien E. Ibrahim, MD, will discuss how recent trial results can be leveraged to save lives with angiotensin receptor-neprilysin inhibition and SGLT2 inhibitors. The session begins at 8:00 ET.
Before finalizing the first-ever ADA/EASD Consensus Report on the management of adults with type 1 diabetes, the writing team led by Anne L. Peters, MD, and Richard I.G. Holt, PhD, FRCP, highlighted key topics addressed in the report at the Scientific Sessions. Read more
Kristen J. Nadeau, MD, MS, outlined the unique cardiometabolic mechanisms and consequences of youth-onset type 1 and type 2 diabetes in her award lecture. Read more
An infectious disease epidemiologist, a journalist, and a researcher—Christina M. Astley, MD, ScD, Gary Schwitzer, and Bertha Hidalgo, PhD, MPH—came together to share their perspectives on communication of risk and its impact on public health and public trust. Read more
An international panel of diabetes prevention researchers including Mike Sampson, MD, Kerri Lynn Knippen, PhD, MPH, RDN, LD, BC-ADM, Pilvikki Absetz, PhD, and Anne M. Wolf, MS, RDN, shared lessons learned from the implementation of type 2 diabetes prevention programs around the world during a symposium Monday. Read more
“We know there are so many people who are getting suboptimal care in terms of diabetes—inpatient and outpatient—because we can’t reach them all. We really need to use technology as a base," said Amisha Wallia, MD, MS. Read more
Join the ADA for two webinars after the 81st Scientific Sessions that will highlight key sessions and abstracts from the meeting. Read more
#ADA2023 Live Coverage
Q&A: First Results of the Effect of Efpeglenatide on Cardiovascular Outcomes
Julio Rosenstock, MD, Hertzel C. Gerstein, MD, MSc, Richard E. Pratley, MD (top row); Renato D. Lopes, MD, PhD, Carolyn S.P. Lam, MBBS, PhD, Kelley R. Branch, MD, MS (second row); Amanda I. Adler, MD, PhD, Naveed Sattar, MD, PhD, and Stefano del Prato, MD, discuss questions from Scientific Sessions attendees following a Monday afternoon symposium on AMPLITUDE-O trial results. View this session and the Q&A discussion on-demand.
#ADA2023 Live Coverage
Q&A: Accelerating Care and Education—Digital Health and Diabetes Support—Patient and Provider Perspectives
Clockwise from top left, Kelly M. Rawlings, MS, Ilias (Elias) Spanakis, MD, CDCES, Carine M. Nassar, MS, RD, CDCES, Marci Butcher, RD, LN, CDCES, FADCES, and Patricia Hathway Montesinos, MSN, APRN, FNP-BC, BC-ADM, CDCES, discuss questions from Scientific Sessions attendees following a Monday afternoon symposium featuring patient and provider perspectives on digital health and diabetes support. View this session and the Q&A discussion on-demand.
#ADA2023 Social Scene
Loading...
#ADA2023 Live Coverage
Monday at #ADA2021: Joint ADA/ASN Symposium
David Cherney, MD, PhD, opens the Joint ADA/ASN Symposium—New Therapies for Kidney Protection in Diabetes. View this session.
Maureen Monaghan, PhD, CDCES, Samantha Kleinberg, PhD, and Jennifer Raymond, MD, MCR, will offer insight into navigating the diabetes digital landscape in a symposium at at 4:30 p.m. ET.
“We hope to give clinicians a comprehensive, comparative view of which drugs do what and in which people,” said GRADE Principal Investigator David Nathan, MD. “It’s about time that we started to find out how these different drugs act in different populations.” GRADE results will be presented at 4:30 p.m. ET.
Outstanding Educator discusses preconception education and diverse communities
Denise Charron-Prochownik, PhD, RN, CPNP, FAAN, speaks about her efforts to educate teenage girls with diabetes about their reproductive health. She also addressed the 81st Scientific Sessions upon receiving the Outstanding Educator in Diabetes Award on Saturday. View her lecture.
#ADA2023 Live Coverage
Q&A: Professional Interest Group Discussion on Health Care Delivery and Quality Improvement—Don’t Forget to Ramp Up and Don’t Hesitate to Slow Down—Clinical Inertia in the Treatment of Diabetes
Clockwise from top left, Kamlesh Khunti, PhD, MD, FRCGP, FRCP, FMedSci, Mary K. Rhee, MD, Alexander Turchin, MD, MS, and Rajesh Garg, MD, discuss questions from Scientific Sessions attendees following the Professional Interest Group Discussion on Health Care Delivery and Quality Improvement. View this session and the Q&A discussion on-demand.
#ADA2023 Live Coverage
Interorgan Cross Talk—Metabolites, Proteins, and Extracellular Vesicles
Jun Wu, PhD, opens a symposium on interorgan cross talk. View this session at ADA2021.org.
At 2:15 p.m. ET, Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk.
Kelly M. Rawlings, MS, and Marci Butcher, RD, LN, CDCES, FADCES, will discuss digital health and diabetes support in a two-hour symposium at 2:15 p.m. ET.
You can Shop Diabetes conveniently from within the Virtual 81st Scientific Sessions meeting platform. Get the latest diabetes titles, including clinical references, cookbooks, and more. Save 30% to 50% on select books. Domestic and international shipping is available.
Carlos A. Monteiro, MD, PhD, will share data on the effects of ultraprocessed foods, while Sung Kyun Park, ScD, MPH, will provide data on per- and polyfluoroalkyl substances in a symposium that begins at 2:15 p.m. ET.
At 2:15 p.m. ET, a joint symposium of the ADA and the International Society for Pediatric and Adolescent Diabetes featuring Richard A. Oram, MD, PhD, and R. Brett McQueen, PhD, will consider general population screening versus targeted screening.
Raghavendra Rao, MD, Charles Stanley, MD, Sarbattama Sen, MD, and Paul Rozance, MD, will address whether neonatal hypoglycemia is overdiagnosed or underestimated in this symposium that begins at 2:15 p.m. ET.
Juleen R. Zierath, PhD, recieves 2021 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes
Juleen R. Zierath, PhD, is the recipient of the 2021 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes. This award honors an individual who has demonstrated outstanding research, evaluation, and care in diabetes performed from an international perspective with an international impact.
An expert panel including Kathryn Haskins, PhD, Teresa P. DiLorenzo, PhD, and Megan K. Levins, PhD, will discuss the past, present, and future of T cells in diabetes treatment in a symposium starting at 2:15 p.m. ET.
ADA Virtual Exhibit Hall and Industry Learning Hub are open
Check out the Virtual Exhibit Hall and Industry Learning Hub during the Scientific Sessions. Search the nearly 60 exhibitor booths by category in the Virtual Exhibit Hall. Engage with Corporate Symposia, Diabetes Learning Bytes, and Product Theaters in the Industry Learning Hub, with many events available on-demand through September 29.
#ADA2023 Live Coverage
Silvio E. Inzucchi, MD, receives 2021 Outstanding Physician Clinician in Diabetes Award
Silvio E. Inzucchi, MD, is the recipient of the 2021 Outstanding Physician Clinician in Diabetes Award. This award is presented to an individual to reward and honor meritorious contributions to diabetes clinical practice.
#ADA2023 Live Coverage
Hans-Henrik Parving, MD, DMSc, receives 2021 Outstanding Achievement in Clinical Diabetes Research Award
Hans-Henrik Parving, MD, DMSc, is the recipient of the 2021 Outstanding Achievement in Clinical Diabetes Research Award. This award recognizes exceptional contributions in patient-oriented clinical outcomes research that have had a significant impact on diabetes prevention and treatment.
#ADA2023 Live Coverage
Professional Interest Group Discussion on Public Health and Epidemiology—Is Diabetes a Risk Factor for Adverse Health Outcomes in Patients with COVID-19?
Elisabetta Patorno, MD, DrPH, begins the Professional Interest Group Discussion on Public Health and Epidemiology. The session considers whether diabetes is a risk factor for adverse health outcomes in patients with COVID-19. View the session at ADA2021.org.
#ADA2023 Live Coverage
Professional Interest Group Discussion on Health Care Delivery and Quality Improvement—Don’t Forget to Ramp Up and Don’t Hesitate to Slow Down—Clinical Inertia in the Treatment of Diabetes
Mary K. Rhee, MD, provides the introduction for a Professional Interest Group Discussion on health care delivery and quality improvement. The session includes a live video question and answer period starting at 12:50 p.m. ET. This discussion will be available for viewing with the on-demand session recording at ADA2021.org within 24 hours.
#ADA2023 Live Coverage
Bruce M. Spiegelman, PhD, receives 2021 Albert Renold Award
Bruce M. Spiegelman, PhD, is the recipient of the 2021 Albert Renold Award. This award is presented to an individual whose career is distinguished by outstanding achievements in the training and mentorship of diabetes research scientists and in the development of communities of scientists to enhance diabetes research.
Outstanding Scientific Achievement Award recipient discusses insulin resistance in youth
Kristen J. Nadeau, MD, MS, speaks about her work treating diabetes in youth. She is the recipient of the 2021 Outstanding Scientific Achievement Award. View her lecture.
Monday morning at #ADA2021: Clinical and Regulatory Hurdles Facing Islet Transplantation
A.M. James Shapiro, MD, PhD, introduces a Monday morning symposium on clinical and regulatory issues related to islet transplantation. View this session.
#ADA2023 Social Scene
Loading...
#ADA2023 Social Scene
Loading...
#ADA2023 Live Coverage
Q&A: Management of Type 1 Diabetes in Adults—2021 Draft ADA/EASD Consensus Report
Kirsten Nørgaard, MD, DMSc, MHPE, J. Hans DeVries, MD, PhD, Richard I.G. Holt, PhD, FRCP, Barbara Ludwig, MD, PhD (top row from left); Amy Hess Fischl, MS, RDN, LDN, BC-ADM, CDCES, Sue Kirkman, MD, Irl B. Hirsch, MD, Tomasz Klupa, MD, PhD (second row from left); Eric Renard, MD, PhD, Frank J. Snoek, PhD, Anne L. Peters, MD, Jay S. Skyler, MD, MACP, FRCP (third row from left); and Ruth S. Weinstock, MD, PhD, (bottom row) discuss questions from Scientific Sessions attendees following a Sunday symposium on the draft of the first ADA/EASD Consensus Report on the management of type 1 diabetes in adults. View this session's presentations and the Q&A discussion on-demand.
#ADA2023 Live Coverage
Q&A: The Year in Review—Highlights of the Past Year in Basic, Translational, and Clinical Sciences
Clockwise from top left, Maureen Gannon, PhD, William T. Cefalu, MD, Julio Rosenstock, MD, and Jay S. Skyler, MD, MACP, discuss questions from Scientific Sessions attendees following a Sunday symposium reviewing highlights of the past year in basic, translational, and clinical sciences. View this session's presentations and the Q&A discussion on-demand.
#ADA2023 Social Scene
Loading...
#ADA2023 Live Coverage
Kristen J. Nadeau, MD, MS, receives 2021 Outstanding Scientific Achievement Award
Kristen J. Nadeau, MD, MS, is the recipient of the 2021 Outstanding Scientific Achievement Award. This award recognizes research in diabetes that demonstrates independence of thought and originality. Dr. Nadeau will present the Outstanding Scientific Achievement Award Lecture on Monday, June 28, at 10:10 a.m. ET.
#ADA2023 Live Coverage
Automation and Expanded Use of Technology in the Inpatient Setting—An Update
Athena Philis-Tsimikas, MD, serves as chair of a symposium discussing new developments in the use of automation and technology in the inpatient setting. View the session at ADA2021.org.
Colin James Greaves, PhD, CPsychol, opens a symposium on challenges to implementing diabetes prevention interventions. Lessoned learned from across the globe will be discussed. View the session at ADA2021.org.
A full educational program awaits on the fourth day of the virtual meeting. Scientific Sessions Meeting Planning Committee Chair Dana Dabelea, MD, PhD, previews the day’s highlights.
The data from continuous glucose monitoring devices can help patients make more informed decisions on lifestyle modifications, insulin dosing, and meal planning. Thomas W. Martens, MD, Dana Gershenoff, MS, RD, CDCES, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, explain how in a session at 8:00 a.m. ET.
Richard I.G. Holt, PhD, FRCP, and Anne L. Peters, MD, and their writing team will summarize the key topics addressed by this trans-Atlantic collaboration. The session, beginning at 8:00 a.m. ET, will include a live video question and answer period.
The story of incretins began in the gut—and then something happened, said Jens Juul Holst, MD, DrMedSci. Islets and the pancreas developed from the gut and remain connected by gut hormones, he noted. Read more
As an early-career scientist, Nicholas J. Wareham, FMedSci, FRCP, FFPHM, MBBS, MSc, PhD, developed a strong interest in diabetes screening and was fascinated by then-emerging details of the links between risk factors and type 2 diabetes. Read more
“One of the lessons from the discovery of insulin is to remind us how important it is for us to support high-risk innovative ideas, new and junior investigators—in addition to more established investigators—and basic, clinical, and translational research,” said ADA President, Medicine & Science, Ruth S. Weinstock, MD, PhD. Read more
“The central nervous system is an important target organ for GLP-1 and GIP pharmacotherapy to affect energy balance,” said Alice Adriaenssens, PhD, in the ADA Diabetes Symposium. Read more
David G. Marrero, PhD, advocated for a social-ecological model to better understand and integrate diabetes care in a symposium focused on preserving mental health across the lifespan of living with this disease. Read more
Kelly M. Rawlings, MS, and Marci Butcher, RD, LN, CDCES, FADCES, will discuss digital health and diabetes support in a two-hour symposium Monday afternoon. Read more
Maureen Monaghan, PhD, CDCES, Samantha Kleinberg, PhD, and Jennifer Raymond, MD, MCR, will offer insight into navigating the diabetes digital landscape. Read more
An expert panel including Kathryn Haskins, PhD, Teresa P. DiLorenzo, PhD, and Megan K. Levins, PhD, will discuss the past, present, and future of T cells in diabetes treatment. Read more
Carlos A. Monteiro, MD, PhD, will share data on the effects of ultraprocessed foods, while Sung Kyun Park, ScD, MPH, will provide data on per- and polyfluoroalkyl substances. Read more
Raghavendra Rao, MD, Charles Stanley, MD, Sarbattama Sen, MD, and Paul Rozance, MD, will address whether neonatal hypoglycemia is overdiagnosed or underestimated in this symposium. Read more
A joint symposium of the ADA and the International Society for Pediatric and Adolescent Diabetes featuring Richard A. Oram, MD, PhD, and R. Brett McQueen, PhD, will consider general population screening versus targeted screening. Read more
The data from continuous glucose monitoring devices can help patients make more informed decisions on lifestyle modifications, insulin dosing, and meal planning. Thomas W. Martens, MD, Dana Gershenoff, MS, RD, CDCES, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, explain how. Read more
#ADA2023 Live Coverage
Diabetes and Metabolism across the Lifespan
Rozalyn M. Anderson, PhD, is the chair of a symposium examining diabetes and metabolism. Among the topics addressed are age-related regulation of energy balance and glucose homeostasis, and nutritional control of immunometabolism. View this session at ADA2021.org.
Catlin Dennis, MPH, Gretchen Piatt, PhD, MPH, Christine H. Wang, PhD, and Sarah Westen, PhD, will come together in a 4:30 p.m. ET session to help quantify the toll the COVID-19 pandemic has taken on diabetes patients and their families.
Data support the use of telehealth and remote monitoring for patients with diabetes. Leslie A. Eiland, MD, Lindsay S. Mayberry, PhD, MS, and Irl B. Hirsch, MD, will outline how to use these tools for different populations in a session beginning at 4:30 p.m. ET.
The symposium will include a review of treatment options for preproliferative diabetic retinopathy by Jennifer Sun, MD, MPH, and an overview of advancements in retinal neurovascular degeneration in diabetes by Patrice E. Fort, PhD, MS. The session begins at 4:30 p.m. ET.
The Year in Review, from 4:30 p.m. – 6:30 p.m. ET, offers a broad look at advancements in basic, clinical, and translational sciences, putting into context recent research and the future of the field. Speakers include Maureen Gannon, PhD, and Jay S. Skyler, MD, MACP.
Q&A: Efficacy and Safety of Dapagliflozin in Patients with and without Type 2 Diabetes Hospitalized with COVID-19— Results from the DARE-19 Global Randomized Controlled Trial
Clockwise from top left, Jennifer B. Green, MD, Carolyn S.P. Lam, MBBS, PhD, Otávio Berwanger, MD, PhD, Subodh Verma, MD, PhD, FRCSC, and Mikhail N. Kosiborod, MD, discuss questions from Scientific Sessions attendees following a symposium on DARE-19 trial results. The session's presentations and the Q&A discussion can be viewed on-demand.
Kelly West Award recipient discusses etiology, public policy
Nicholas J. Wareham, FMedSci, FRCP, FFPHM, MBBS, MSc, PhD, reflects on his career in the diabetes community. He is the recipient of the 2021 Kelly West Award for Outstanding Achievement in Epidemiology. View his lecture on-demand at ADA2021.org.
#ADA2023 Live Coverage
All Roads Lead to Insulin
Debbie C. Thurmond, PhD, opens a symposium discussing various aspects of insulin. View this session at ADA2021.org.
#ADA2023 Live Coverage
Children with Type 2 Diabetes Are Not Just Little Adults
Kenneth C. Copeland, MD, serves as chair of a symposium on type 2 diabetes in pediatric patients. View this session at ADA2021.org.
Q&A: Professional Interest Group Discussion on Diabetes Self-Management Education and Support (DSMES)— Post-Pandemic Care for Patients with Diabetes in a Diverse Population
Ashby F. Walker, PhD, and Beverly Thomassian, RN, MPH, CDCES, BC-ADM, answer questions from Scientific Sessions attendees during a live video question and answer period following the Professional Interest Group Discussion on Diabetes Self-Management Education and Support. The presentations and Q&A discussion can be viewed on-demand at ADA2021.org.
DARE-19 Principal Investigator Mikhail Kosiborod, MD, will provide the first look at a subgroup analysis of type 2 diabetes patients who are at higher risk for developing serious complications from COVID-19 in a session beginning at 2:15 p.m. ET.
Nicholas J. Wareham, FMedSci, FRCP, FFPHM, MBBS, MSc, PhD, receives 2021 Kelly West Award
Nicholas J. Wareham, FMedSci, FRCP, FFPHM, MBBS, MSc, PhD, is the recipient of the 2021 Kelly West Award for Outstanding Achievement in Epidemiology. This award recognizes significant contributions to the field of diabetes epidemiology. Dr. Wareham will deliver the Kelly West Award Lecture on Sunday, June 27, at 2:15 p.m. ET.
#ADA2023 Social Scene
Loading...
#ADA2023 Live Coverage
Professional Interest Group Discussion on Eye Health—Ocular Health Care by Telehealth and Artificial Intelligence (AI)
George L. King, MD, opens the Professional Interest Group Discussion on Eye Health. The session includes information on the use of telehealth and artificial intelligence in ocular health care. View the session at ADA2021.org.
#ADA2023 Live Coverage
Professional Interest Group Discussion on Diabetes Self-Management Education and Support (DSMES)— Post-Pandemic Care for Patients with Diabetes in a Diverse Population
Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP, serves as chair for a Professional Interest Group Discussion on diabetes self-management education and support as it relates to care for a diverse population of people with diabetes in a post-pandemic era. The session includes a live video question and answer period starting at 12:55 p.m. ET. This discussion will be available for viewing with the on-demand session recording at ADA2021.org within 24 hours.
Banting Medal recipient reflects on gut hormones, obesity
Jens Juul Holst, MD, DrMedSci, speaks about his contributions to the diabetes community as a trailblazing incretin researcher. View the Banting Medal Lecture.
Clockwise from top left, Dana Lewis, BA, Anna Norton, MS, Natalie J. Bellini, MSN, FNP-BC, Jordan Sherwood, MD, and David M. Maahs, MD, PhD, discuss questions posed by Scientific Sessions attendees during a live question and answer period Sunday morning. The presentations and Q&A discussion can be viewed on-demand at ADA2021.org.
#ADA2023 Social Scene
Loading...
#ADA2023 Live Coverage
Jens Juul Holst, MD, DrMedSci, receives 2021 Banting Medal for Scientific Achievement
Jens Juul Holst, MD, is the recipient of the 2021 Banting Medal for Scientific Achievement. This award recognizes significant, long-term contributions to the understanding, treatment, or prevention of diabetes. Dr. Holst will present the Banting Medal Lecture on Sunday, June 27, at 11:00 a.m. ET.
ADA President, Medicine & Science, reflects on telehealth, diabetes in older adults
ADA President, Medicine & Science, Ruth S. Weinstock, MD, PhD, speaks about some of the ADA's ongoing efforts and future plans. She will address the 81st Scientific Sessions beginning at 10:15 a.m. ET Sunday, June 27. View the session at ADA2021.org.
Dana M. Lewis, BA, shared details about her presentation at the 81st Scientific Sessions on evidence supporting the use of open-source automated insulin delivery systems. "Many providers are still unaware of them as an option, or how they might support patients choosing to access these systems," she said.
Read more
Shuibing Chen, PhD, shared details about this presentation, which begins Sunday, June 27, at 6:00 p.m. ET. Read more
#ADA2023 Live Coverage
Q&A: Carbohydrate Counting—Still Useful with Evolving Insulin Delivery Technologies?
Becky Sulik, RDN, LD, CDCES, Kirstine Bell, APD, CDE, PhD, Holly Willis, PhD, RDN, LD, and Bruce A. Buckingham, MD, answer questions from Scientific Sessions attendees during a live video discussion following a Saturday symposium on the role of carbohydrate counting amind evolving insulin delivery technology. The presentations and Q&A discussion can be viewed on-demand at ADA2021.org.
#ADA2023 Live Coverage
Matchmaker, Matchmaker, Make Me a Match—Selecting Glucose-Lowering Combinations for Type 2 Diabetes Mellitus
Richard E. Prately, MD, is the chair of a symposium on glucose-lowering options for patients with type 2 diabetes that lasts until 10:00 a.m. ET. View this session at ADA2021.org.
Subscribe to get regular news updates about the Scientific Sessions.
You can also subscribe to receive other email communications from the American Diabetes Association.